Cormedix Inc. last reported quarterly results on Nov 2, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026). It usually reports 8–44 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 7, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Jan 8, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 8–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 2, 2026
33 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
—
|
—
|
—
|
|
Aug 13, 2026
44 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
102
+156.5%
|
26
+31.1%
|
0.29
+3.6%
|
|
May 14, 2026
44 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
127
+226.1%
|
39
+87.0%
|
0.43
+43.3%
|
|
Jan 8, 2026
8 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
129
+312.1%
|
14
+4.1%
|
-0.06
+19.9%
|
|
Oct 20, 2025
20 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
102
+786.4%
|
109
+4009.6%
|
1.26
+2620.0%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
40
+4829.4%
|
20
+240.1%
|
0.28
+212.0%
|
|
Apr 8, 2025
8 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
39
|
21
+242.7%
|
0.30
+220.0%
|
|
Jan 7, 2025
7 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
31
+104976.3%
|
13
+191.3%
|
-0.08
+69.5%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CRMD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Parsippany, NJ
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1410098
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.